AU2004202858B2 - FSH mimetics for the treatment of infertility - Google Patents
FSH mimetics for the treatment of infertility Download PDFInfo
- Publication number
- AU2004202858B2 AU2004202858B2 AU2004202858A AU2004202858A AU2004202858B2 AU 2004202858 B2 AU2004202858 B2 AU 2004202858B2 AU 2004202858 A AU2004202858 A AU 2004202858A AU 2004202858 A AU2004202858 A AU 2004202858A AU 2004202858 B2 AU2004202858 B2 AU 2004202858B2
- Authority
- AU
- Australia
- Prior art keywords
- substituted
- substituents
- aryl
- cycloalkyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000000509 infertility Diseases 0.000 title claims description 14
- 230000036512 infertility Effects 0.000 title claims description 14
- 231100000535 infertility Toxicity 0.000 title claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 92
- 125000003118 aryl group Chemical group 0.000 claims description 82
- 125000001424 substituent group Chemical group 0.000 claims description 82
- 125000000623 heterocyclic group Chemical group 0.000 claims description 76
- 241000894007 species Species 0.000 claims description 76
- -1 carboxy, formyl Chemical group 0.000 claims description 75
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 63
- 125000003342 alkenyl group Chemical group 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 20
- 125000002252 acyl group Chemical group 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 14
- 125000005140 aralkylsulfonyl group Chemical group 0.000 claims description 14
- 125000003435 aroyl group Chemical group 0.000 claims description 14
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 14
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 14
- 125000005518 carboxamido group Chemical group 0.000 claims description 14
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 14
- 125000004043 oxo group Chemical group O=* 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000004104 aryloxy group Chemical group 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 claims description 9
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 9
- 125000004414 alkyl thio group Chemical group 0.000 claims description 9
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims description 9
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 9
- 125000005110 aryl thio group Chemical group 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 6
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 125000004001 thioalkyl group Chemical group 0.000 claims description 6
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000011160 research Methods 0.000 claims description 4
- 125000003003 spiro group Chemical group 0.000 claims description 4
- 230000001270 agonistic effect Effects 0.000 claims description 3
- 230000001817 pituitary effect Effects 0.000 claims description 3
- 101150068906 snr-6 gene Proteins 0.000 claims description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 2
- 229940046989 clomiphene citrate Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- LTUFGCFAPCJOFQ-UHFFFAOYSA-N 2h-pyran-3-carboxamide Chemical compound NC(=O)C1=CC=COC1 LTUFGCFAPCJOFQ-UHFFFAOYSA-N 0.000 claims 3
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- AIQAFLYKJANIJF-UHFFFAOYSA-N CCCCCC1=CC=C(C(N)=O)C(=O)O1 Chemical compound CCCCCC1=CC=C(C(N)=O)C(=O)O1 AIQAFLYKJANIJF-UHFFFAOYSA-N 0.000 claims 1
- KEGDILSCBGAASQ-UHFFFAOYSA-N CNC1=C(C(OC(=C1)CCCCC)=O)C(=O)NC Chemical compound CNC1=C(C(OC(=C1)CCCCC)=O)C(=O)NC KEGDILSCBGAASQ-UHFFFAOYSA-N 0.000 claims 1
- 102000006771 Gonadotropins Human genes 0.000 claims 1
- 108010086677 Gonadotropins Proteins 0.000 claims 1
- 239000002622 gonadotropin Substances 0.000 claims 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 54
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 54
- 229940028334 follicle stimulating hormone Drugs 0.000 description 54
- 150000001408 amides Chemical class 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 32
- 239000000556 agonist Substances 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 238000003556 assay Methods 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000011347 resin Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 108010060374 FSH Receptors Proteins 0.000 description 9
- 102000008175 FSH Receptors Human genes 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 210000002503 granulosa cell Anatomy 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 7
- 229960005309 estradiol Drugs 0.000 description 7
- 229930182833 estradiol Natural products 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 4
- SIRPVCUJLVXZPW-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)NC(C(=O)O)CC1=CN=CN1 SIRPVCUJLVXZPW-UHFFFAOYSA-N 0.000 description 4
- NYCDSJNKGZMFSX-UHFFFAOYSA-N 2-oxo-6-pentylpyran-3-carboxylic acid Chemical compound CCCCCC1=CC=C(C(O)=O)C(=O)O1 NYCDSJNKGZMFSX-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000009151 Luteinizing Hormone Human genes 0.000 description 4
- 108010073521 Luteinizing Hormone Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 229940040129 luteinizing hormone Drugs 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 3
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 3
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 125000002015 acyclic group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 3
- 150000001923 cyclic compounds Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 2
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 2
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 2
- 101100347605 Arabidopsis thaliana VIII-A gene Proteins 0.000 description 2
- 101100347612 Arabidopsis thaliana VIII-B gene Proteins 0.000 description 2
- 101100025412 Arabidopsis thaliana XI-A gene Proteins 0.000 description 2
- MOCSPUDHCSJDIO-UHFFFAOYSA-N CCN1C2=C(C=C(C=C2)NC(=O)C(C)NC)C3=CC=CC=C31 Chemical compound CCN1C2=C(C=C(C=C2)NC(=O)C(C)NC)C3=CC=CC=C31 MOCSPUDHCSJDIO-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- NPBRSLAHQSXGQZ-UHFFFAOYSA-N 1-(2-oxochromene-3-carbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C(=O)C1=CC2=CC=CC=C2OC1=O NPBRSLAHQSXGQZ-UHFFFAOYSA-N 0.000 description 1
- HJPAPBLWOHRSJS-UHFFFAOYSA-N 1-(4-butoxybenzoyl)pyrrolidine-2-carboxylic acid Chemical compound C1=CC(OCCCC)=CC=C1C(=O)N1C(C(O)=O)CCC1 HJPAPBLWOHRSJS-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- JQAOHGMPAAWWQO-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCCCC1C(O)=O JQAOHGMPAAWWQO-UHFFFAOYSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-M 2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)[O-])C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-M 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- LZNNMMKMGKFYLL-UHFFFAOYSA-N 2h-pyran-3-carboxylic acid Chemical compound OC(=O)C1=CC=COC1 LZNNMMKMGKFYLL-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- BENKAPCDIOILGV-UHFFFAOYSA-N 4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CC(O)CC1C(O)=O BENKAPCDIOILGV-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- GEBHJZSTCHHEQT-UHFFFAOYSA-N C(C)N(C(=O)C=1C(OC(=CC1)CCCCC)=O)CC(NC=1C=CC=2N(C3=CC=CC=C3C2C1)CC)=O Chemical compound C(C)N(C(=O)C=1C(OC(=CC1)CCCCC)=O)CC(NC=1C=CC=2N(C3=CC=CC=C3C2C1)CC)=O GEBHJZSTCHHEQT-UHFFFAOYSA-N 0.000 description 1
- RQPIYEQBSZMDMY-UHFFFAOYSA-N C(C)N1C2=CC=CC=C2C=2C=C(C=CC12)NC(=O)C(CC1=CC=CC=C1)N(C(=O)C=1C(OC(=CC1)CCCCC)=O)C Chemical compound C(C)N1C2=CC=CC=C2C=2C=C(C=CC12)NC(=O)C(CC1=CC=CC=C1)N(C(=O)C=1C(OC(=CC1)CCCCC)=O)C RQPIYEQBSZMDMY-UHFFFAOYSA-N 0.000 description 1
- BHXGATSQDSERGL-UHFFFAOYSA-N C1=CC(CCCCC)=CC=C1C(=O)N1C(C(O)=O)CCC1 Chemical compound C1=CC(CCCCC)=CC=C1C(=O)N1C(C(O)=O)CCC1 BHXGATSQDSERGL-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 102100027627 Follicle-stimulating hormone receptor Human genes 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 102000017357 Glycoprotein hormone receptor Human genes 0.000 description 1
- 108050005395 Glycoprotein hormone receptor Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000862396 Homo sapiens Follicle-stimulating hormone receptor Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 101100459301 Mus musculus Myl4 gene Proteins 0.000 description 1
- MVZROEXHXCESQB-UHFFFAOYSA-N NC(N)=O.CC(C)N=C=NC(C)C Chemical compound NC(N)=O.CC(C)N=C=NC(C)C MVZROEXHXCESQB-UHFFFAOYSA-N 0.000 description 1
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100037342 Substance-K receptor Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000003911 Thyrotropin Receptors Human genes 0.000 description 1
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid Chemical compound OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 150000001924 cycloalkanes Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- UPXAZUFKXWLNMF-UHFFFAOYSA-N n'-propan-2-ylmethanediimine Chemical compound CC(C)N=C=N UPXAZUFKXWLNMF-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- LBQAJLBSGOBDQF-UHFFFAOYSA-N nitro azanylidynemethanesulfonate Chemical compound [O-][N+](=O)OS(=O)(=O)C#N LBQAJLBSGOBDQF-UHFFFAOYSA-N 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004911 positive regulation of CREB transcription factor activity Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000002810 primary assay Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000002805 secondary assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION STANDARD PATENT Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Invention Title: FSH MIMETICS FOR THE TREATMENT OF INFERTILITY The following statement is a full description of this invention, including the best method of performing it known to us: 2 FSH Mimetics for the Treatment of Infertility
BACKGROUND
This application claims the benefit of U.S. Provisional Application No.
60/095,712, filed August 7, 1998.
Field The present invention relates to non-peptidic amino derivatives, their therapeutic use, as well as pharmaceutical compositions comprising these derivatives.
In particular, the invention relates to cyclic and acyclic alpha- and betaaminocarboxamides. The compounds of the invention possess activity as Follicle Stimulating Hormone (FSH) agonists and are useful in the treatment of infertility.
Summary of the Related Art Annually in the U.S. there are 2.4 million couples experiencing infertility that are potential candidates for treatment. Follicle stimulating hormone, either extracted from urine or produced by recombinant DNA technology, is a parenterally-administered protein product used by specialists for ovulation induction (01) and for controlled ovarial hyperstimulation (COH). Whereas 01 is directed at achieving a single follicle to ovulate, COH is directed at harvesting multiple oocytes for use in various in vitro assisted reproductive technologies for in vitro fertilization). Clinical use of preparations containing FSH began in the 1960's.
Follicle stimulating hormone (FSH) is a pituitary-derived heterodimeric glycoprotein hormone that shares structural similarities with luteinizing hormone (LH) and thyroid stimulating hormone (TSH), both of which are also produced in the pituitary gland, and chorionic gonadotropin which is produced in the placenta. The hormones are relatively large (28-38 kilodaltons) and are composed of a common a subunit non-covalently bound to a distinct p subunit that confers receptor binding specificity.
The cellular receptors for these hormones are known to be members of the G protein-coupled class of membrane-bound receptors, which when activated stimulate an increase in the activity of adenylyl cyclase. This results in an increase in the level of the intracellular second messenger adenosine 5'-monophosphate (cAMP), which in turn causes increased steroid synthesis and secretion. Hydropathicity plots of the amino acid sequences of these receptors reveal three general domains: a hydrophilic amino-terminal region, considered to be the amino-terminal extracellular domain, seven hydrophobic segments of membrane- spanning length, considered H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 3 to be the transmembrane domain, and a carboxy-terminal region that contains potential phosphorylation sites (serine, threonine, and tyrosine residues), considered to be the carboxy-terminal intracellular or cytoplasmic domain. The glycoprotein hormone receptor family is distinguished from other G protein-coupled receptors, such as the p2-adrenergic, rhodopsin, and substance K receptors, by the large size of the hydrophilic amino-terminal domain, which is involved in hormone binding.
The FSH receptor is expressed on testicular Sertoli cells and ovarian granulosa cells. While there has been a recognized need for providing essentially pure human FSH receptor, purification of naturally derived preparations is not practical and would likely be insufficient to permit determination of the amino acid sequence. Recently, one group has cloned the cDNA encoding the rat FSH receptor, deduced the amino acid sequence, and expressed it in mammalian cells (Sprengel, Mol. Endocrinol. 4: 525 (1990)). Another group, attempting to clone the TSH receptor, apparently also cloned and identified a portion of the transmembrane region of the human FSH receptor (Parmentier, Science 246: 1620 (1989)).
Use of FSH is limited by its high cost, lack of oral dosing, and need of extensive monitoring by specialist physicians. Hence, identification of a non-peptidic small molecule substitute for FSH that could potentially be developed for oral administration is desirable.
SUMMARY
We have now found non-peptidic compounds for the treatment of infertility that mimic the action of FSH. Such compounds have superior convenience of use compared to FSH due to their oral bioavailability. They are suitable for prescription by a Ob/Gyn, require minimal supervision, and have substantially lower costs compared to FSH treatment.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 depicts the scheme for the synthesis of the compounds of Formula XVI and Formula XVII.
Figure 2 depicts the scheme for the synthesis of the compound of Formula
XVIII.
Figure 3 depicts the scheme for the synthesis of the compound of Formula XIX.
Figure 4 depicts the scheme for the synthesis of the compound of Formula
XXV.
Figure 5 depicts the scheme for the synthesis of the compound of Formula
XXVI.
H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 4 Figure 6 displays the results of LDR analysis of compounds XVI, XVII, and XIX, compared to FSH.
Figure 7 displays the results of the primary rat granulosa cell bioassay for compounds XVI and XVII, compared to FSH.
DETAILED DESCRIPTION The present application relates to a general class of non-peptidic amino derivative having the general structure of Formula I, R3
R
4
I
Y W I I
R
5 Z R'/N R 2 wherein,
R
1
R
3
R
4 and R 5 are each independently hydrogen, C 1
-C
10 alkyl, C 1
-C
1 0 alkyl substituted with one or more substituents, C 2
-C
1 0 alkenyl, C 2
-C
10 alkenyl substituted with one or more substituents, C 2
-C
1 0 alkynyl, C 2
-C
10 alkynyl substituted with one or more substituents, C 1
-C
8 alkoxy, C 1
-C
8 alkoxy substituted with one or more substituents, C 2
-C
8 alkoxycarbonyl, C 2
-C
8 alkoxycarbonyl substituted with one or more substituents, C 1
-C
8 thioalkyl, C 1
-C
8 thioalkyl substituted with one or more substituents,
C
2
-C
8 acyl, C 2
-C
8 acyl substituted with one or more substituents, C 2
-C
8 acyloxy, C 2
-C
8 acyloxy substituted with one or more substituents, aryloxy, aryl, aryl substituted with one or more substituents, C 3
-C
7 cycloalkyl, C 3
-C
7 cycloalkyl substituted with one or more substituents, C 3
-C
7 heterocycle, or C 3
-C
7 heterocycle substituted with one or more substituents, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic or aromatic ring;
R
2 is hydrogen, straight or branched Cl-C 6 alkyl or C 3
-C
7 cycloalkyl or C3-C 7 cycloalkyl substituted with one or more substituents, C 3
-C
7 heterocycle, C 3
-C
7 heterocycle substituted with one or more substituents, aryl, aryl substituted with one or more substituents, heteroaryl, heteroaryl substituted with one or more substituents, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic or aromatic ring; or R 2 together with R' forms a C 2
-C
7 heterocycle, C 2
-C
7 heterocycle substituted with one or more substituents, heteroaryl, or heteroaryl substituted with one or more substituents; W is carbonyl amido amidoalkyl (NH(C=0)CH 2 imino (C=NH), thiocarbonyl sulfonyl (SO 2 methylene (CH 2 or methylene substituted with one H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 or more substituents; X is CH or N; Y is CH or N; and Z is carbonyl amino imino sulfonyl (SO 2 or (C=0)NH; or Z, together with R 1 N, W, X, and Y, forms a Cs-C7 heterocyclic ring in which R 1 is a direct bond or a C1-C2 alkylene.
With reference to Formula I, FSH agonists are cyclic compounds wherein Z together with R 1 N, W, X, and Y form a C5-C7 heterocyclic ring in which R 1 is a direct bond or a C1-C2 alkylene and which is substituted with one or more substituents, R3
R
4 1
/X
Y W
RZ-R
1
-N
I I Also with reference to Formula I, additional FSH agonists are cyclic compounds wherein R 2 and R 3 form a C5-C7 heterocycle substituted with one or more substituents: R3 -R 2
III
R
5 z Within this general class the present invention provides compounds of Formula
IV-A,
R
3
R
9 I I Z N
R
5 R1 N R 2
IV-A
and pharmaceutically acceptable addition salts thereof, wherein:
R
3 and R 9 are each independently hydrogen, halogen, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, Ci-C5 alkyl or alkenyl or arylalkyl imino, azido, H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 -6mercapto, carboxamido, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, C1-C alkyl, C1-C8 alkenyl, C1-C8 alkoxy, C-C8 alkoxycarbonyl, C2-C8 acyl, 01-08 alkylthio, arylalkylthio, arylthio, C1-C8 alkylsulfinyl, arylalkylsulfinyl, arylsulfinyl, C1-C8 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, C1-C N-alkyl carbamoyl, C2-C15 N,N-dialkylcarbamoyl, C1-C5 alkyl or alkenyl or arylalkyl ester, C1-C7 cycloalkyl, aroyl, aryloxy, benzyloxy, benzyloxy substituted with one or more substituents, aryl, aryl substituted with one or more substituents, C3-C7 heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic or aromatic ring; or R 3 and R 9 are each independently -NR6R7 or -(CH2),NRrR 7 where s is 1-6 and R6 and R 7 are as defined in section of the definition of substituent, below; or
R
3 and R 9 together form a substituted or unsubstituted C3-C7 cycloalkyl or C3-C7 heterocycle spiro ring, or such a ring fused to a cycloalkyl, heterocyclic or aromatic ring, to make a compound of Formula IV-B, Y pW I I R N R2
IV-B
R
1 is a carbazolyl substituted with one or more substitutents;
R
5 is a heterocyclic ring substituted with one or more substitutents;
R
4 is hydrogen, C 1
-C
1 0 alkyl, C 1
-C
1 0 alkyl substituted with one or more substituents, C2- Clo alkenyl, C 2 -Co 10 alkenyl substituted with one or more substituents, C2-C 1 0 akynyl, C2- Co akynyl substituted with one or more substituents, C1-C8 alkoxy, C1-C8 alkoxy substituted with one or more substituents, C2-C8 alkoxycarbonyl, C2-C8 alkoxycarbonyl substituted with one or more substituents, C-C8 thioalkyl, C1-C8 thioalkyl substituted with one or more substituents, C2-C8 acyl, 02-08 acyl substituted with one or more substituents, C2-C8 acyloxy, C2-C8 acyloxy substituted with one or more substituents, aryloxy, aryl, aryl substituted with one or more substituents, C3-C7 cycloalkyl, C3-C7 cycloalkyl substituted with one or more substituents, C3-C7 heterocycle, or C3-C7 heterocycle substituted with one or more substituents, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic or aromatic ring;
R
2 is hydrogen, straight or branched C1-C6 alkyl or C3-C7 cycloalkyl or C3-C7 cycloalkyl substituted with one or more substituents, C3-C7 heterocycle, C3-C7 heterocycle substituted with one or more substituents, aryl, aryl substituted with one or more H:\ShonaI\Keep\Speci\P534?8 DIVISIONAL SPECI 25/06/04 -7 substituents, heteroaryl, heteroaryi substituted with one or more substituents, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic or aromatic ring; W is carbonyl amido amidoalkyl (NH(C=0)0H2-), imino (C=NH), thiocarbonyl sulfonyl (SO 2 methylene (OH 2 or methylene substituted with one or more substituents; Y is OH or N; Z is carbonyl amino imino sulfonyl (S02), or (0=O)NH; and the substituents for R 3 and R 4 are independently halogen, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, 01-05 alkyl or alkenyl or arylalkyl imino, carbamoyl, azido, carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, 0 1
-C
8 alkyl, 0j-08 alkenyl, Cj-08 alkoxy, 01-08 alkoxycarbonyl, aryloxycarbonyl, 0 2
-O
8 acyl, 01-08 alkylthio, arylalkylthio, arylthio, 0j- 08 alkylsulfinyl, arylalkylsulfinyl, arylsulfinyl, Cj-08 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, 01-06 N-alkyl carbamoyl, C2-C15 N, N-dialkylcarbamoyl, 03-07 cycloalkyl, aroyl, aryloxy, arylalkyl ether, aryl, aryl fused to a cycloalkyl or heterocycle or another aryl ring, C3-C7 heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic, or aromatic ring; or NR3R where R 6 and R 7 are each independently hydrogen, cyano, oxo, carboxamido, amidino, Cj-08 hydroxyalkyl, Cl-C 3 alkylaryl, aryl-0 1
-O
3 alkyl, Cj-C8 alkyl, 0l-Ca alkenyl, 01-08 alkoxy, 01-C8 alkoxycarbonyl, aryloxycarbonyl, aryl- 01-03 akoxycarbonyl, 02-0s acyl, 0l-O8 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, aroyl, aryl, aryl fused to a cycloalkyl or heterocyclic or another aryl ring, 03-07 cycloalkyl, C3- 07 heterocycle, or any of these rings fused or spiro-fused to a cycloakyl or heterocyclic or aromatic ring; or R 6 and R 7 are taken together to form -(0H 2 )mB(0H 2 )n where B is -0(H)(R 8
N(R
8 or where m and n are independently 1 to 3, r is 0 to 2, and R 8 is defined the same way as R3; or -(0H 2 ),NR 6 R 7 where s is 1-6 and R3 and R 7 are as defined in section of the definition of substituent, above; and the substituents for R 5 are independently halogen, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, Cjalkyl or alkenyl or arylalkyl imino, carbamoyl, azido, carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, 0 1
-C
8 alkyl, 01-083 alkenyl, 01-08 alkoxy, Cj- 08 alkoxycarbonyl, aryloxycarbonyl, 02-08 acyl, 01-08 alkylthio, arylalkylthio, arylthio, 01-08 alkylsulfinyl, arylalkylsulfinyl, arylsulfinyl, 01-08 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, 0l-Cr, N-alkyl carbamoyl, 02-015 N, N-dialkylcarbamoyl, 03-07 cycloalkyl, aroyl, aryloxy, arylalkyl ether, aryl, aryl fused to a cycloalkyl or heterocycle or another Hb\Shona1\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 8 aryl ring, C3-C7 heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic, or aromatic ring; or
-NR
6
R
7 where R 6 and R 7 are each independently hydrogen, cyano, oxo, carboxamido, amidino, C1-C8 hydroxyalkyl, C1-C 3 alkylaryl, aryl-C1-C 3 alkyl, C0-C8 alkyl, C-C8 alkenyl, C0-Cs alkoxy, C 1
-C
8 alkoxycarbonyl, aryloxycarbonyl, aryl- C1-C3 akoxycarbonyl, C1-C8 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, aroyl, aryl, aryl fused to a cycloalkyl or heterocyclic or another aryl ring, C3-C7 cycloalkyl, C3-C7 heterocycle, or any of these rings fused or spiro-fused to a cycloakyl or heterocyclic or aromatic ring; or R 6 and R 7 are taken together to form -(CH 2 )mB(CH 2 )n where B is -C(H)(R 8
-N(R
8 or where m and n are independently 1 to 3, r is 0 to 2, and R 8 is defined the same way as R 6 or
-(CH
2 )sNR6R 7 where s is 1-6 and R 6 and R 7 are as defined in section of the definition of substituent, above.
The present application also generally describes FSH agonists which are compounds of Formula V,
R
9
YI
R
5 Z R1N
R
2
V
wherein R 3 and R 4 together with the C and Y to which they are bound, respectively, form a substituted or unsubstituted aryl, substituted or unsubstituted C3-C 7 cycloalkyl or C3-C7 heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic or aromatic ring, and R 1
R
2
R
3
R
5
R
9 W, Y, and Z are as defined for Formula I.
Also with reference to Formula I, additional FSH agonists are cyclic aaminocarboxamides wherein X CH, Y N, and R 3 and R 4 together with the carbon and nitrogen atoms to which they are attached form a heterocyclic or heteroaromatic ring, H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 9 B A R2 N W R'
/Z
R
VI
wherein R 1
R
2
R
5 W and Z are as defined for Formula I; n 0 or 1; and A and B are each independently -CH 2 or where R 1 0 is hydrogen, hydroxy, amino, amino substituted with one or more substituents, C0-C6 alkoxy, C-C6 alkyl, C 1
-C
6 alkyl substituted with one or more substituents, C1-C6 alkoxycarbonyl, cyano, Ci-Ce aminoalkyl, or -(CH 2 )sNR 6
R
7 where s, R 6 and R 7 are as defined for Formula I.
Additional FSH agonists described in the application are compounds of Formula VII,
IR
R4
X
Y W R1N R 2
VII
wherein R 3 and W form a substituted or unsubstituted aryl, substituted or unsubstituted C3-C7 cycloalkyl, C3-C7 heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic or aromatic ring, and R 1
R
2
R
4
R
5 X, Y, and Z are as defined for Formula I.
With reference to generally described Formulae III and V, or V and VII, FSH agonists are compounds wherein rings are combined to form fused bicyclic rings, R3- R 2 4 Y \W NR1 or I N R5 R 5 R "-R2
R
5 VIII-A
VIII-B
wherein the rings in VIII-A and VIII-B are defined the same way as the corresponding rings in Formulae III, V, and VII.
H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 10 With reference to generally described Formulae I and V, additional FSH agonists include compounds wherein Y N and R 3 and R 4 together with the carbon and nitrogen atoms to which they are attached form a heterocyclic or heteroaromatic ring, R12 R M R13 (n "k R14 N W I I Z N
R
5
R
1
R
2
IX
wherein R 1 R R 5
R
9 W, and Z are as defined for Formula I;
R
1 1
R
12 and R 1 3 are defined the same way as R 9 and additionally, each of R 9
R
1 2 and R 1 3 either independently or in combination are capable of forming a spiro or fused or bridged ring; n 0 or 1; and L and M are independently CH, N, O, or S, provided L and M are not both heteroatoms and when L is 0 or S there is no R 1 3 and when M is 0 or S there is no R 2 With reference to Formulae I and IV, FSH agonists also include acyclic aaminocarboxamides and spiro-ring containing ca-aminocarboxamides of Formula X, R2
R
3
R
9 R 2 N
I
R5Z O R5
R
5 X-A X-B wherein R 1
R
2
R
3
R
4
R
5
R
9 Z and the spiro ring are as defined for Formulae I and
IV.
With reference to generally described Formulae I and VII, FSH agonists also include 2,3-diamino aryl or heteroaryl groups substituted with one or more substituents that are optionally fused to a cycloalkyl, heterocyclic, or aryl ring substituted with one or more substituents, H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 11 ID1 R 13 R" E E
TY
I I
R
2 R 1 R5 R 2
R
1 XI-A XI-B wherein E Y C or N;
R
1 R 2 R 4 R 5
R
6
R
11 R 1 2 R 13 B, Y and Z are as defined for Formulae I and IX; and n 0 or 1.
Additional FSH agonists are cyclic alpha-amino carboxamides that contain a heterocyclic or heteroaromatic ring,
R
5 0o
XII
wherein R 1 R 2
R'
5 n, A, and B are as defined for Formula V1.
Other FSH agonists based on Formula IX are cyclic alpha-amino carboxamides that contain a heterocyclic or heteroaromatic ring, N R13 0
R
5 0 wherein R 2 R R 9
R'
1
R
12
R
13 n, L, and M are as defined for Formula IX, and H:\ShonaI\Keep\sPeci\P53478 DIVISIONAL SPECI 25/06/04 12 additionally, R 11 and R 1 2 together may form a fused substituted or unsubstituted aromatic ring.
Additional FSH agonists based on Formula IX are cyclic compounds wherein W is amido rather than carbonyl (Formula XIII-A): R12 I R13 R" M LR13 |n N R N R2
R
5 0
XIII-A
FSH agonists based on Formula XIII-A are compounds of Formula XIII-B,
R
12 R /R13 R" M L O 0 N N
R
5 R14/N R16
XIII-B
wherein R 14 and R 15 are defined the same way as R 9 in Formula IV-A and R 1 6 is defined the same way as R 2 in Formula I.
FSH agonists related to compounds of Formula XIII-B are compounds of Formula XIII-C, N X9N R17 N R14 R16
XIII-C
H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 13 wherein R 14 and R 16 are as defined for Formula XIII-B and R 1 7 is defined the same way as R 2 in Formula I.
The present invention further provides FSH agonists based on Formula X are acyclic alpha-amino carboxamides or spiro-ring substituted alpha-aminocarboxamides, wherein either R 3 or R 9 is not hydrogen, R12
R
3
CH
3 R2 R M 13 N R or R2 S 0 R4 R/ 4VR1 I ]F "R RsZ
O
XIV-A
XIV-B
wherein
R
2
R
3
R
4
R
5 and Z are as defined for formula IV-A; M is CH, N, O, or S, provided when M is O or S there is no R12
R"
1
R
1 2 and R 13 are each independently hydrogen, halogen, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, C,-C 5 alkyl or alkenyl or arylalkyl imino, azido, mercapto, carboxamido, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, C 1
-C
8 alkyl, C,-Cs alkenyl, C,-C8 alkoxy, C1-C alkoxycarbonyl, C2-Ca acyl, 1-C8 alkylthio, arylalkylthio, arylthio, C1-C8 alkylsulfinyl, arylalkylsulfinyl, arylsulfinyl, C-C alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, C1-C6 N-alkyl carbamoyl, C2-C15 N,N-dialkylcarbamoyl, alkyl or alkenyl or arylalkyl ester, Cl-C7 cycloalkyl, aroyl, aryloxy, benzyloxy, benzyloxy substituted with one or more substituents, aryl, aryl substituted with one or more substituents, C3-C7 heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic or aromatic ring, or -NR 6
R
7 or -(CH 2
)NR
6
R
7 where s is 1-6 and
R
6 and R 7 are as defined in section of the definition of substituent; or
R
11
R
12 and R 1 3 each either independently or in combination are a spiro, fused, or bridged ring.
FSH agonists based on Formula XI are 2-amino-3-carboxamido pyridines or the bicyclic analogs thereof, H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 14 N I or> N q N R 2
RR
1 R 2
R
1 XV-A XV-B wherein R 1 R 2 R 4
R
5 R 6
R
11 R 12 R 13 and B are as defined for Formulae XI-A and
XI-B.
Specific examples of compounds of Formula IX include the following: 1 -[(2-Oxo-6-pentyl-2H-pyran )-3-carbonyll-3-hyd roxypyrrolidine-2-carboxylic acid-3-(9-ethylcarbazolyl)amide; 1 -[(2-Oxo-6-pentyl-2H-pyran )-3-carbonyl]-3-acetoxypyrrolidine-2-carboxyl ic acid-3-(9-ethylcarbazolyl)amide; 1 -[(2-Oxo-6-isopropyl-2H-pyra n)-3-ca rbonyl]-p ipe rid i ne-2-ca rboxyl ic acid-3-(9ethylcarbazolyl)amide; 1 -[(2-Oxo-6-n-propyl-2H-pyran)-3-carbonyl]-piperidine-2-carboxylic acid-3-(9ethyl ca rbazolyl)a mid e; 1 -[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]-piperid ine-2-carboxylic acid-2-(3indolyl)ethylamide; 3-[(2-Oxo-6-pentyl-2H-pyran )-3-carbonyl]-2,2-dimethylthiazolidine-4-carboxylic acid-3-(9-ethyl ca rbazoyl)a mid e; 3-[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]-5,5-dimethylthiazolid ine-4-carboxylic acid-3-(9-ethylcarbazolyl)amide; 1 -[(2-Oxo-6-pentyl-2H-pyran )-3-carbonyl]-4-methylpiperizi ne-2-carboxylic acid- 3-(9-ethylcarbazolyl)amide; 2-[1 -Ca rboxamido-2-(3H-imidazoi-4-yl)ethyicarba moyl]-N-(2-ethyl-nhexylamino) tetrahydroisoq uinoline; 1 -[(2-Oxo-6-pentyi-2H-pyran)-3-carbonyl]-2-methyl pyrrolidine-2-carboxyl ic acid- 3-(9-ethylcarbazolyl) amide; 1 -[(2-Oxo-6-pentyl-2H-pyran )-3-carbonyl]-4-hydroxypyrrolid ine-2-carboxy ic acid-3-(9-ethylcarbazolyl) amide; 1 -[(2-Oxo-6-pentyl-2H-pyran )-3-carbonyl]-4-acetoxypyrrolid ine-2-ca rboxyl ic acid-3-(9-ethylcarbazolyl) amide; 3-[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]thiazolidine-4-carboxylic acid-3-(9- H:\Shona1\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 15 ethyl ca rbazolyl) amide; 3-[(2-Oxo-6-pentyi-2H-pyran)-3-carbonyl]- 1,1 -d joxo-thiazolid ine-4-carboxyi ic acid-3-(9-ethylcarbazolyl) amide; 3-[(2-Oxo-6-pentyl-2H-pyran )-3-carbonyl]thiazolid ine-2-carboxyi c acid-3-(9ethylcarbazolyl) amide; 1 -(Benzofuran-2-yI)carbonyl- pyrrolidine-2-carboxylic acid-3-(9-ethyl carbazolyl)amide; 1 -[(2-Oxo-6-methyl-2H-pyran )-3-carbonyl]-trans-3-azabicyclo(3. 1.0)hexane-2carboxylic acid-3-(9-ethylcarbazolyl)amide; 1 -[(2-Oxo-6-pentyl-2H-pyra n)-3-carbonyl]4-oxopyrrolidine-2-carboxylic acid-3- (9-ethylcarbazolyl)amide; 2-[(2-Oxo-6-pentyl-2H-pyran )-3-carbonyl]7-hyd roxytetrahydroisoq uinol ine-3carboxylic acid-3-(9-ethylcarbazolyl)amide; 2-[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]tetrahydroisoquinoline-3carboxylicacid-3-(9-ethylcarbazolyl)amide; 1 -[(2-Oxo-6-pentyl-2H-pyran )-3-carbonyl]azetid ine-2-carboxyl ic acid-3-(9ethylcarbazolyl)amide; 1 -[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl] 3,4-dehyd ropyrrolidine-2-carboxyicacid (9-ethylca rbazolyl)a mide; 1 -(2-Oxo-2H-chromene-3-carbonyl)-pyrrolidine-2-carboxylic acid-3-(9ethyl ca rbazolyl)a mid e; 1 ,3-Dioxo-2-isoindolineacetyl)- piperidine-2-carboxylic acid-3-(9ethyl ca rbazolyl)a mid e; 1 Fl uoro-4-trifl uoromethyl be nzoyl)-p ipe rid ine-2-ca rboxyl ic acid-3-(9ethylcarbazolyl)amide; 1 -(4-n-Pentylbenzoyl)-pyrrolidine-2-carboxylic acid-3-(9-ethylcarbazolyl)amide; 1 -(4-n-butoxybenzoyl)-pyrrolidine-2-carboxylic acid-3-(9-ethylcarbazolyl)amide; 1 Pentyl benzoyl methyl)-pi pe rid ine-2-carboxyl ic acid-3-(9ethylcarbazolyl)amide; 1 -[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]-2-oxo-imidazolidine-5-carboxylic acid- 3-(9-ethylcarbazolyl)amide; 1 -[(2-Oxo-6-pentyl-2H-pyran )-3-carbonyl]-2-[(9-ethylcarbazolyl)ami nomethyl] pyrrolidine; 1 -[(2-Oxo-6-phenyl-2H-pyran)-3-carbonyl]-pyrrolidine-2-carboxylic acid-3-(9ethyl ca rbazolyl)a mid e; I -[(2-Oxo-6-methyl-2H-pyran)-3-carbonyl]-pyrrolidine-2-carboxylic acid-3-(9ethyl ca rbazolyl)a mid e; H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 16 1 -[(2-Oxo-6-p he nyl-2H-pyra n)-3-ca rbonyl]-pi pe rid ine-2-carboxyl ic acid-3-(9ethylcarbazolyl)amide; and 1 -[2-Oxo-6-methyl-2H-pyra n)-3-ca rbonyl]-pi pe rid ine-2-carboxyl ic acid-3-(9ethylcarbazolyl)amide; or a pharmaceutically acceptable addition salt thereof.
Specific examples of compounds of Formula X11 include the following: 2-fl -Carboxamido-2-(3H-imidazol-4-yl)ethylcarbamoyl]-2-(2-ethyl-nhexylamino)tetraline; 2-(2-Ethyl-n-hexyl)-N-[(1 -carboxamido-2-terazolyl)ethyl]-3isoquinolinecarboxamide; 1 -[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]pyrrolidine-2-carboxylic acid-3-(9ethyl ca rbazolyl)a mid e; and 1 -[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]piperidine-2-carboxylic acid-3-(9ethyl ca rbazolyl)a mid e; or a pharmaceutically acceptable addition salt thereof.
Specific examples of compounds represented by Formula XIII include the following: 1 -[(2-Oxo-6-pentyl-2H-pyran )-3-carbonyl] pyrrolid ine-2-carboxyl ic acid-3-(9ethyl ca rbazolyl) amide (Formula XVI), N% 0
H-
H
3 G 0 0 KCH 3
XIV'
which can exist in two enantiomeric forms (the asterisk denotes the chiral center); 1 -[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]piperidine-2-carboxylic acid-3-(9-ethyl carbazolyl)amide (Formula XVII), 0 N-a 00
N
3 5 H 3CCc) 0K H 3 Xv"l H:\Shona 1\Keep\Speci \P5 34 78 DIVISIONAL SPECI 25/06/04 17 which can exist in two enantiomeric forms (the asterisk denotes the chiral center); 2-(2-Ethyl-n-hexyl)-N-[(1 -carboxamido-2-terazolyl)ethyll-3isoquinolinecarboxamide (Formula XVIII), N NN 0H,N WVin 1 -[(2-Oxo-6-pentyl-2H-pyra n)-3-carbonyl]-4-hyd roxypyrrol id ine-2-carboxyl ic acid-3-(9-ethylcarbazolyl) amide (Formula XIX),
H
N
N~ N 0 0 N H 1 -[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]-2-methylpyrrolidine-2-carboxylicacid- 3-(9-ethylcarbazolyl) amide (Formula XX),
H
HG 00 0CHH 30 0
H
XX
1 -[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]-2-[3-(9-ethylcarbazolyl )ami nomethyl] pyrrolidine Formula XXI), H:\Shona1\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 18
N
0 0
H
3 C 0 00
~CH
3
XX'
2-[1 -Carboxamido-2-(3H-imidazol-4-yl)ethylcarbamoyl]-N-(2-ethyl-nhexylamino) tetrahydroisoquinoline (Formula XXII),
XXII
or a pharmaceutically acceptable addition salt thereof.
The present invention provides specific examples of compounds represented by Formula XIV include the following: 1 -[3-(9-Ethylcarbazolyl)carbamoyl]ethylamino-N-methyl-(2-oxo-6-pentyl-2Hpyran-3-carboxamide) (Formula XXII11) and 1 -Methyl-i ethyl ca rbazolyl )ca rba moyl] -ethyla m ino-N-methyl-(2-oxo-6-pe ntyl-2H-pyra n-3carboxamide) (Formula XXIV), H R12
H
3
C-NXO
N
300 3 C 0 0 C3 XXIII (R 1 2 XXIV (912 =CHO) I -[3-(9-Ethylca rbazolyl)carbamoyl]ethylamino-N-methyl-(2-oxo-6-pentyl-2Hpyran-3-carboxamide); 1 -Methyl-I -[3-(9-ethylcarbazolyl)carbamoyl]-ethylamino-N-methyl-(2-oxo-6pen tyl-2H-pyran-3-ca rboxam id e); H:\Shona1\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 19 1 Ethyl ca rbazolyl)ca rbamoyl] isoa myla m ino-N-methyl-(2-oxo-6- pentyl-2Hpyran-3-carboxamide); 1 -[3-(9-Ethylcarbazolyl)carbamoyllisobutylamino-N-methyl-(2-oxo-6-pentyl-2Hpyran-3-carboxamide); 1 -[3-(9-Ethylcarbazolyl)carbamoyl]phenylethylamino-N-methyl-(2-oxo-6-pentyl- 2H-pyran-3-carboxamide); 1 Ethyl ca rbazol yl )ca rba moyl] 2-hyd roxyethylam mino-N-methyl-(2-oxo-6pentyl-2H-pyran-3-carboxamide); 1 Ethyl ca rbazolyl)ca rba moyll methyla m ino-N-methyl-(2-oxo-6-pentyl-2Hpyran-3-carboxamide); 1 -[3-(9-Ethylcarbazolyl )carbamoyl] methylami no-N-ethyl-(2-oxo-6-pentyl-2Hpyran-3-carboxamide); and 1-Methyl-I -[3-(9-ethylcarbazolyl )carbamoyl]-ethylamino-(2-oxo-6-pentyl-2Hpyran-3-carboxamide); or a pharmaceutically acceptable addition salt thereof.
Specific examples of compounds represented by Formula XV include the following: 3-(9-ethylcarbazolyl)amino-pyridin-2-yl-3-(2-oxo-6-pentyl-2H-pyran-3carboxamide) (Formula XXVI) and 3-(9-ethylcarbazolyl)amino-pyridin-2-yl-3-(N-methyl- 2-oxo-6-pentyl-2H-pyran-3-carboxamide) (Formula X)(VI I),
N
H
3 C 0 0 N
H
XXVI (R 1 2 XXVII (R' 2
CHO)
3 0 or a pharmaceutically acceptable addition salt thereof.
It will be appreciated by those skilled in the art that compounds of the invention may contain a chiral center, and thus will exist in two enantiomeric forms. The present invention includes the use of the individual enantiomers and mixtures of the enantiomers. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereomeric complexes or derivatives which may be separated, for example, by crystallization or chromatographic separation.
Alternatively, specific enantiomers; may be synthesized by asymmetric synthesis using H; Shona 1\Keep\Speci \P5347 8 DIVISIONAL SPECI 25/06/04 20 optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
The non-peptidic amino derivatives of the present invention represent small molecule substitutes for FSH for the treatment of infertility. The invention therefore comprises a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier, diluent, or excipient thereof.
The invention further comprises a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier, diluent, or excipient thereof in combination with FSH.
The invention further comprises a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier, diluent, or excipient thereof in combination with the anti-estrogen compound Clomiphene citrate (Cassidenti et al. (1992) Hum. Reprod., 7: 344-348).
The invention further comprises a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier, diluent, or excipient thereof in combination with human chorionic gonadotropin (hCG) or human pituitary leutenizing hormone (LH) (Breckwoldt et al. (1971) Fert. Steril., 22: 451-455; Diedrich et al. (1988) Hum. Reprod., 3: 39-44).
The invention further comprises use of a compound of the present invention for the preparation of a medicament.
The invention further comprises a method for treating infertility comprising administering an effective FSH agonistic amount of any of said compounds or pharmaceutical compositions.
The invention further comprises use of a compound of pharmaceutical composition in the manufacture of a medicament to treat infertility.
The invention further comprises use of a compound or pharmaceutical composition to treat infertility.
As FSH agonists, the compounds of the invention are also useful research tools to study the role of FSH and the FSH receptor in biological processes in vitro.
Chemical Syntheses Processes for the preparation of the compounds of Formula I are described hereinafter. Such processes comprise reacting a compound of Formula XXVIII, H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 21 R2
N
H R 1
XXVIII
with a compound of Formula XXIX,
R
3
R
4
X
Y E
R
XXIX
wherein R 1
R
2
R
3
R
4
R
5 X, Y, and Z are defined as for Formula I and E represents a functional group such as SO 2 CI, CHO, COOH, COCI, NCO, CN, N C-CI, CH 2 CI, or
CH
2 0-tosylate.
The compounds of the invention may be prepared by the methods described below and in Examples 1-5. The synthetic schemes displayed in Figures 1-5 illustrate how compounds according to the invention can be made. Those skilled in the art will be able to routinely modify and/or adapt the methods and schemes presented herein to synthesize any compound of the invention.
Pharmaceutical Preparations Pharmaceutical compositions comprising a compound of Formulas I to XXIX and a pharmaceutically acceptable carrier, diluent or excipient therefore are generally described. Thus, the present invention also provides compounds for use as a medicament. In particular, the invention provides the compounds of the present invention for use as FSH agonists, for the treatment of infertility, either alone or in combination with other medicaments. In in vitro assays these compounds were found to mimic the actions of FSH since they exhibit positive log dose response in the screening assay (CHO luciferase FSHR) and are negative in the control assay (CHO luciferase). Accordingly, the compounds of the invention are useful research tools for studying the role of FSH in biological processes.
The representative compounds also show activity in the primary rat granulosa cell H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 22 bioassay, which is used to detect the conversion of testosterone to estradiol in the presence of FSH or an FSH agonist. The CHO luciferase assay and the rat granulosa cell bioassay are described in detail hereinafter.
The compounds of the invention, together with a conventional adjuvant, carrier, diluent or excipient may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous use). Such pharmaceutical compositions and unit dosage forms thereof may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. Tablets containing 10 milligrams of active ingredient or, more broadly, 0.1 to 100 milligrams, per tablet, are accordingly suitable representative unit dosage forms.
Definitions The following paragraphs provide definitions of various chemical moieties described throughout the specification and are intended to apply uniformly throughout the specification and claims unless expressly stated otherwise.
The term "substituent" refers to halogen, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, C1-C 5 alkyl or alkenyl or arylalkyl imino, carbamoyl, azido, carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, C1-C8 alkyl, C1-C8 alkenyl, C1-C8 alkoxy, Cl- Ce alkoxycarbonyl, aryloxycarbonyl, C2-C8 acyl, C1-C8 alkylthio, arylalkylthio, arylthio, C1-C8 alkylsulfinyl, arylalkylsulfinyl, arylsulfinyl, C1-C8 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, C1-C6 N-alkyl carbamoyl, C2-C15 N,N-dialkylcarbamoyl, C3-C7 cycloalkyl, aroyl, aryloxy, arylalkyl ether, aryl, aryl fused to a cycloalkyl or heterocycle or another aryl ring, C3-C7 heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic, or aromatic ring; or
NR
6
R
7 where R 6 and R 7 are each independently hydrogen, cyano, oxo, carboxamido, amidino, Cl-C8 hydroxyalkyl, C-C3 alkylaryl, aryl-C 1
-C
3 alkyl, CI-Cs alkyl, C-C8 alkenyl, C1-C8 alkoxy, Cl-C8 alkoxycarbonyl, aryloxycarbonyl, aryl-Ci-C 3 alkoxycarbonyl, C2-C8 acyl, Ci-C8 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, aroyl, aryl, aryl fused to a cycloalkyl or heterocyclic or another aryl ring, C3-C7 cycloalkyl, C3- C7 heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl or heterocyclic or aromatic ring; H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 23 or where R 6 and R 7 are taken together to form -(CH2)mB(CH2)n where B is
-C(H)(R
8
-N(R
8 or where m and n are independently 1 to 3, r is 0 to 2, and R 8 is defined the same way as R 6 or
-(CH
2 )sNR 6
R
7 where s is 1-6 and R 6 and R 7 are defined as in section (b) of the definition of substituent, above.
The term "substituted" refers to the moiety substituted with one or more substituents.
The term "alkyl" refers to a univalent C1 to C 8 saturated straight, branched, or cyclic alkane moiety and specifically includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, 3methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl. The alkyl group can be optionally substituted with any appropriate group, including but not limited to one or more moieties selected from the group consisting of halo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art or as taught, for example, in Greene, et al., "Protective Groups in Organic Synthesis," John Wiley and Sons, Second Edition, 1991.
The term "cycloalkyl" refers to a monocyclic C3-C7 ring.
The terms "arylalkyl" and "alkylaryl" refer to groups in which the alkyl consists of between 1 and 3 carbons.
The term "alkoxy" refers to an alkyl moiety having a terminal with free a valence, CH 3
CH
2 The term "alkenyl" refers to a univalent C 2
-C
6 straight, branched, or in the case of C-6, cyclic hydrocarbon with at least one double bond, optionally substituted as described above.
The term "alkynyl" refers to a univalent C2 to C6 straight or branched hydrocarbon with at least one triple bond (optionally substituted as described above) and specifically includes acetylenyl, propynyl, and -C-C-CH 2 (alkyl), including -C-C-
CH
2
(CH
3 The term "aryl" refers to a mono- or bi- or tri-cyclic aromatic ring system that may optionally be substituted with one or more substituents.
The term "heteroatom" means N, O, or S.
The term "heterocycle" refers to a cyclic alkyl, alkenyl, or alkynyl moiety wherein one or more ring carbon atoms is replaced with a heteroatom; a Cm-Cn heterocycle is a ring that contains m to n members wherein one or more of the members is a heteroatom.
The term "heteroaryl" refers to a aryl moiety wherein one or more ring carbon H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 24 atoms is replaced with a heteroatom.
The term "halo" refers to chloro, fluoro, iodo, or bromo.
When a substituent defined as a monovalent radical becomes incorporated into a ring R 2 and R 3 on Formula III), it is understood that the substituents become the corresponding divalent radicals.
The term "pharmaceutically acceptable salts or complexes" refers to salts or complexes that retain the desired biological activity of the above-identified compounds and exhibit minimal or no undesired toxicological effects. Examples of such salts include, but are not limited to acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, methanesulfonic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid. The compounds can also be administered as pharmaceutically acceptable quaternary salts known by those skilled in the art, which specifically include the quaternary ammonium salt of the formula -NR wherein R is hydrogen, alkyl, or benzyl, and Z is a counterion, including chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamoate, mandeloate, benzyloate, and diphenylacetate).
The term "pharmaceutically active derivative" refers to any compound that upon administration to the recipient, is capable of providing directly or indirectly, the compounds disclosed herein.
Examples The following Examples further illustrate specific aspects of the compounds disclosed in this application. It is to be understood, however, that these examples are included for illustrative purposes only and are not intended to limit the scope of the invention in any respect and should not be so construed.
Example 1: Synthesis of 1-[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]-pyrrolidine-2carboxylic acid-3-(9-ethyl carbazolyl)amide (Formula XVI) (Figure 1; Scheme 1) Step A. Synthesis of 1-[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]-pyrrolidine-2carboxylic acid-t-butylester: To a solution of Boc-L-Proline (5 mmol, Advanced ChemTech, Louisville, USA) in dichloromethane (20 mL) cooled to 0 oC were added dropwise a solution of di- H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 25 isopropyl carbodiimide (DIC, 2.5 mmol). After the solution had been stirred at 0 °C for min, the solid by-product (DIC urea) was filtered out. To the filtrate were added 3amino-9-ethylcarbazole (5 mmol, Aldrich Chemical Company, Milwaukee, USA) in DMF and triethyl amine (5 mmol) and the solution was stirred at room temperature for 16 h. The reaction was monitored by TLC for completion. The solution was evaporated to dryness under vacuum. The residue was dissolved in ethyl acetate (250 mL) and washed successively with 10% aqueous sodium carbonate, 10% aqueous citric acid, water, and saturated brine. The organic layer was dried on anhydrous sodium sulfate, filtered and ethyl acetate was evaporated to give an oily product 1-(t- Butoxycarbonyl)-N-[3-(9-ethylcarbazolyl)]-2-pyrrolidinecarboxamide (75% yield); HPLC purity: 90%; Mass: desired M+H found (Perceptive Biosystem's Voyager-Maldi TOF).
This compound was used in the next step without further purification.
Step B. Formation of 1-[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]-pyrrolidine-2carboxylic acid-3-(9-ethyl carbazolyl)amide (Formula XVI): The N-Boc-pyrrolidine carboxamide obtained from step A was dissolved in trifluoroacetic acid/dichloromethane (25 mL) and stirred for 30 min at room temperature. The TFA solution was evaporated under vacuum. The dry residue was dissolved in DMF and two equivalents of triethyl amine was added, followed by one equivalent of a symmetrical anhydride (generated in situ from 2-oxo-6-pentyl-2H-pyran- 3-carboxylic acid and diisopropylcarbodi-imide) and the solution was stirred for 14 h.
DMF was evaporated under high vacuum. The residue was dissolved in ethyl acetate.
This organic layer was washed with 10% aqueous sodium carbonate, 10% aqueous citric acid, water and saturated brine. The organic layer was dried on anhydrous magnesium sulphate. The organic layer was decolorized with charcoal evaporated under vacuum to result in light brown gummy material. This crude material was purified on preparative reverse phase HPLC using 1% TFA-acetonitrile and water as the mobile phase. HPLC purity 95%. Mass: calculated for C 3 0
H
33
N
3 0 4 499.6; found: 500.6 (Perceptive Biosystem's Voyager-Maldi TOF).
Synthesis of 1-[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]-piperidine-2-carboxylic acid-3-(9-ethyl carbazolyl)amide (Formula XVII) was achieved using the same procedure as above by using N-boc-pipecolinic acid made from dl-pipecolinic acid (Aldrich Chemical Company, Milwaukee, USA) in place of Boc-L-proline.
Example 2: Synthesis of 2-(2-Ethyl-n-hexyl)-N-[(1-carboxamido-2-terazolyl)ethyl]-3isoquinolinecarboxamide (Formula XVIII) (Figure 2; Scheme 2) Step A. Synthesis of amide of Rink amide resin and N-Fmoc-D-histidine: Fmoc-amino Rink Amide resin (1.0 g, 0.45 mmol/g substitution), available from H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 26 NovaBiochem (San Diego, USA), was swollen with dichloromethane for 10 min. The resin was further washed with dimethyl formamide three times. The Fmoc- group was removed with 20% piperidine in DMF for 30 min. Further repeated washings were done with DMF (3 x 2 min), dichloromethane (DCM, 3 x 2 min), DMF (1 x 1 min). Then N-Fmoc-D-histidine (available from Advanced ChemTech, Louisville, USA) in DMF mL, 2.0 mmol (4 equivalents with respect to the resin loading)], 2 mmol of 0-(7azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and 4 mmol of diisopropylethylamine (DIEA, 640 pL) were added to the resin to make a slurry. This slurry was stirred at room temperature for 2 h. The small resin sample was subjected to Sarin-Kaiser test for the completion of reaction. The resin was then filtered and washed with DMF (3 x 2 min), MeOH(2 x 2 min), dichloromethane (2 x 2 min) and DMF (2 x 2 min).
Step B. Synthesis of N-[(1-Carboxamido-2-tetrazoyl)ethyl]-3-isoquinolinecarboxamide bound to Rink amide resin: The compound obtained from step A was deprotected by removal of the Fmocgroup with 20% piperidine in DMF for 30 min. Further resin washings were done with DMF (3 x 2 min), dichloromethane (DCM, 3 x 2min), DMF (1 x 1 min). Then 1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid (available from Advanced ChemTech, Louisville, USA) in DMF [10 mL, 2.0 mmol (4 equivalents with respect to the resin loading)], 2 mmol of HATU and 4 mmol of diisopropylethylamine (DIEA, 640 p.L) were added to the resin to make a slurry. This slurry was stirred at room temperature for 2 h. The small resin sample was subjected to Sarin-Kaiser test for the completion of reaction. The resin was then filtered and washed with DMF (3 x 2 min), MeOH (2 x 2 min), dichloromethane (2 x 2 min) and DMF (2 x 2 min).
Step C. Synthesis of 2-(2-Ethyl-n-hexyl)-N-[(1-carboxamido-2-terazolyl)ethyl]- 3-isoquinolinecarboxamide bound to resin: The Fmoc- group on the tetrahydroisoquinoline nitrogen was removed by treatment with 20% piperidine in DMF for 30 min. The resin was then washed with DMF (3 x 2 min), dichloromethane (3 x 2 min), and DMF (1 x 1 min). Then a 0.2 M stock solution of 2-ethylhexanal (Aldrich Chemical Company, Milwaukee, USA) in 2% Acetic acid in trimethyl ortho formate (TMOF) (10 mL/g of resin) was added and reaction was carried out for 2 h to form an imine derivative in situ. Then a 0.2 M stock solution of sodium cyanoborohydride (NaCNBH 3 in TMOF was added to the above reaction mixture to get the final concentration to 0.1 M and the reaction was continued at room temperature for 14 h. The resin was washed with TMOF (3 x 2 min), DMF (3 x 2 min), MeOH (3 x 2 min), dichloromethane (2 x 2 min) and dried under vacuum for 4 h.
H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 27 Step D. Formation of 2-(2-Ethyl-n-hexyl)-N-[(1-carboxamido-2-terazolyl)ethyl]- 3-isoquinoline carboxamide (Formula XVIII): Pre-cooled cleavage reagent (trifluoroacetic acid dimethylsulfide triisopropylsilane :H 2 0; 90:2.5:2.5:5; v/v) was added (10 mL/g) to the dried resin and allowed to stir for 2 h at room temperature. The TFA cocktail was filtered into a 20 mL vial and TFA was evaporated on a rotavapor under vacuum. Diethyl ether was added to precipitate the compound along with trityl alcohol. The mixture was dissolved in acetonitrile before purification on reverse phase HPLC.
Step E. Purification of compound XVIII: The crude compound from step D was dissolved in 10% aqueous acetonitrile and loaded onto the C18 column on Delta preparative HPLC. A linear gradient with 1% TFA acetonitrile and water was used as mobile phase. HPLC purity 95%; Mass (Perceptive Biosystem's Voyager-Maldi TOF): calculated for C 24
H
35
N
5 0 2 425.6; found: 426.6 Example 3: Synthesis of 1-[(2-Oxo-6-pentyl-2H-pyran)-3-carbonyl]-4hydroxypyrrolidine-2-carboxylic acid-[3-(9-ethyl carbazolyl)] amide (Formula XIX) (Figure 3; Scheme 3) Step A. Synthesis of 1-t-butoxycarbonyl-4-hydroxypyrrolidine-2-carboxylic acid- [3-(9-ethyl carbazolyl)] amide: To a solution of N-Boc-trans-hydroxy-L-proline (5 mmol, Sigma Chemical Company, St. Louis, USA) in dichloromethane (20 mL) at ambient temperature were added at 5 min intervals 2-(1 H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, 5 mmol), diisopropyl ethyl amine (DIEA, 10 mmol) followed by 3-amino-9-ethylcarbazole (5 mmol, Aldrich Chemical Company, Milwaukee, USA). After stirring for 1 h, the solution was evaporated to dryness under vacuum. The residue was dissolved in ethyl acetate (250 mL) and washed successively with 10% aqueous sodium carbonate, 10% aqueous citric acid, water, and saturated brine. The organic layer was dried on anhydrous sodium sulfate, filtered and ethyl acetate was evaporated to give an oily product 1-(t-butoxycarbonyl)- 4hydroxypyrrolidine-2-[3-(9-ethyl carbazolyl)] carboxamide (85% yield); HPLC purity: This compound was used in the next step without further purification.
Step B. Formation of 1-[3-(2-Oxo-6-pentylpyran)carbonyl]-4hydroxypyrrolidine-2-carboxylic acid-3-(9-ethyl carbazolyl)amide: The 1-(t-butoxycarbonyl)- 4-hydroxypyrrolidine-2-[3-(9-ethyl carbazolyl)] carboxamide obtained from step A was dissolved in 50 trifluoro acetic acid/dichloromethane (25 mL) and stirred for 30 min at room temperature. The TFA H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 28 solution was evaporated under vacuum. The dry residue was dissolved in dichloromethane and added to the activated ester of 2-oxo-6-pentyl-2H-pyran-3carboxylic acid (generated in situ from 5 mmol 2-oxo-6-pentyl-2H-pyran-3-carboxylic acid, 5 mmol HBTU and 10 mmol diisopropylethylamine) and the solution was stirred for 1 h. The solvent was evaporated under vacuum and the residue was dissolved in ethyl acetate. This organic layer was washed with 10% aqueous sodium carbonate, aqueous citric acid, water and saturated brine. The organic layer was dried on anhydrous magnesium sulphate and then evaporated in vacuo to result in light brown gummy material. This crude material was purified on preparative reverse phase HPLC using 1% TFA-acetonitrile and water as the mobile phase. HPLC purity 95%. Mass: calculated for C 30
H
33
N
3 0: 415.6; found: 516 (Perceptive Biosystem's Voyager- Maldi TOF).
Example 4: Synthesis of 2-[(1-Carboxamido-2-terazolyl)ethylcarbamoyl]-(D,L)-2-(2ethyl-n-hexylamino)tetraline (Formula XXV) (Figure 4; Scheme 4) Step A. Synthesis of amide of Rink amide resin and N-Fmoc-D-histidine: Fmoc-amino Rink Amide resin (1.0 g, 0.45 mmol/g substitution), available from NovaBiochem (San Diego, USA), was swollen with dichloromethane for 10 min. The resin was further washed with dimethyl formamide three times. The Fmoc group was removed with 20% piperidine in DMF for 30 min. Further repeated washings were done with DMF (3 x 2 min), dichloromethane (DCM, 3 x 2 min), DMF (1 x 1 min). Then N-Fmoc-D-histidine (available from Advanced ChemTech, Louisville, USA) in DMF mL, 2.0 mmol (4 equivalents with respect to the resin loading)], 2 mmol of 0-(7azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and 4 mmol of diisopropylethylamine (DIEA, 640 giL) were added to the resin to make a slurry. This slurry was stirred at room temperature for 2 h. The small resin sample was subjected to Sarin-Kaiser test for the completion of reaction. The resin was then filtered and washed with DMF (3 x 2 min), MeOH (2 x 2 min), dichloromethane (2 x 2 min) and DMF (2 x 2 min).
Step B. Synthesis of 2-[(1-Carboxamido-2-tetrazoyl)ethylcarbamoyl]-(D,L)-2aminotetraline bound to Rink amide resin: The compound obtained from step A was deprotected by removal of the Fmoc group with 20% piperidine in DMF for 30 min. Further resin washings were done with DMF (3 x 2 min), dichloromethane (DCM, 3 x 2 min), DMF (1 x 1 min). Then Fmoc- (D,L)-2-Aminotetraline-2-carboxylic acid (available from Acros) in DMF [10 mL, mmol (4 equivalents with respect to the resin loading)], 2 mmol of HATU and 4 mmol of diisopropylethylamine (DIEA, 640 piL) were added to the resin to make a slurry. This H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 29 slurry was stirred at room temperature for 2 h. The small resin sample was subjected to Sarin-Kaiser test for the completion of reaction. The resin was then filtered and washed with DMF (3 x 2 min), MeOH (2 x 2 min), dichloromethane (2 x 2 min) and DMF (2 x 2 min).
Step C. Synthesis of 2-[(1-Carboxamido-2-terazolyl)ethylcarbamoyl]-(D,L)-2-(2ethyl-n-hexylamino)tetraline bound to resin: The Fmoc group on the aminotetraline nitrogen was removed by treatment with piperidine in DMF for 30 min. The resin was then washed with DMF (3 x 2 min), dichloromethane (3 x 2 min), and DMF (1 x 1 min). Then a 0.2 M stock solution of 2ethylhexanal (Aldrich Chemical Company, Milwaukee, USA) in 2% Acetic acid in trimethyl ortho formate (TMOF) (10 mL/g of resin) was added and the reaction was carried out for 2 h to form an imine derivative in situ. Then a 0.2 M stock solution of sodium cyanoborohydride (NaCNBH 3 in TMOF was added to the above reaction mixture to get the final concentration to 0.1 M and the reaction was continued at room temperature for 14 h. The resin was washed with TMOF (3 x 2 min), DMF (3 x 2 min), MeOH (3 x 2 min), dichloromethane (2 x 2 min) and dried under vacuum for 4 h.
Step D. Formation of 2-[(1-Carboxamido-2-terazolyl)ethylcarbamoyl]-(D,L)-2-(2ethyl-n-hexylamino)tetraline (Formula XXV): Pre-cooled cleavage reagent (trifluoroacetic acid dimethylsulfide:triisopropylsilane: H 2 0; 90:2.5:2.5:5; v/v) was added (10 mL/g) to the dried resin and allowed to stir for 2 h at room temperature. The TFA cocktail was filtered into a 20 mL vial and TFA was evaporated on a rotavapor under vacuum.
Diethyl ether was added to precipitate the compound along with trityl alcohol. The mixture was dissolved in 20% acetonitrile before purification on reverse phase HPLC.
Step E. Purification of compound XXV: The crude compound from step D was dissolved in 10% aqueous acetonitrile and loaded onto the C18 column on Delta preparative HPLC. A linear gradient with 1% TFA acetonitrile and water was used as mobile phase. HPLC purity 95%; Mass (Perceptive Biosystem's Voyager-Maldi TOF): calculated for C 2 5
H
37
N
5 0 2 439.6; found: 440.6 Example 5: Synthesis of 3-(9-ethylcarbazolyl)amino-pyridin-2-yl-3-(2-oxo-6-pentyl-2Hpyran-3-carboxamide) (Formula XXVI) (Figure 5; Scheme Step A. Synthesis of 2-[3-(9-ethylcarbazolyl)amino]-3-nitropyridine: To a solution of 2-chloro-3-nitropyridine (5 mmol, Aldrich Chemical Company, Milwaukee, USA) in toluene (10 mL) at ambient temperature were added 3-amino-9ethylcarbazole (5 mmol, Aldrich Chemical Company, Milwaukee, USA). The mixture H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 30 was heated to reflux for a period of 16 h. After cooling to room temperature, the mixture was diluted with ethyl acetate and washed successively with saturated sodium bicarbonate and brine. The organic layer was collected, dried over anhydrous sodium sulphate and concentrated in vacuo to give an oily product. This product was purified by chromatography over silica gel (eluent: 1:1 ethyl acetate:hexane) to give ethylcarbazolyl)amino]-3-nitropyridine (68% yield); HPLC purity: This compound was then used in the next step.
Step B. Synthesis of 2-[3-(9-ethylcarbazolyl)amino]-3-aminopyridine: To a methanolic solution of 2-[3-(9-ethylcarbazolyl)]amino-3-nitropyridine obtained from step A were added 10% palladium over carbon (10% and the mixture was subjected to hydrogenation using a Parr hydrogenator at 40 psi for a period of 12 h.
Then the slurry was filtered over Celite to remove the catalyst and the methanolic filtrate was evaporated to dryness to afford an oily product, ethylcarbazolyl)amino]-3-aminopyridine. This was used as such in the next step.
Step C. Formation of 3-(9-ethylcarbazolyl)amino-pyridin-2-yl-3-(2-oxo-6-pentyl- 2H-pyran-3-carboxamide) (Formula XXVI): To a solution of 2-oxo-6-pentyl-2H-pyran-3carboxylic acid (3mM, Aldrich Chemical Company, Milwaukee, USA) in 10 mL dichloromethane at ambient temperature were added 2-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU; 3 mM; Advanced ChemTech, Louisville, USA) followed by 6 mM of diisopropylethylamine (DIEA; Aldrich Chemical Company, Milwaukee, USA). After 10 minutes, a solution of 3 mM of 2-[3-(9-ethylcarbazolyl)]amino-3aminopyridine (obtained from step B) in 10 mL dichloromethane was added dropwise, and the resulting mixture was stirred at room temperature for 2 h. The crude product mixture was washed with brine, dried over anhydrous sodium sulphate and chromatographed over silica gel (eluent: 1:1 ethyl acetate:hexane to 100% ethyl acetate) to afford 71% of pure compound XXVI. HPLC purity 95%. Mass: calculated for C 30
H
30
N
4 0 3 495; found: 496 (Finnigan LCQ).
Example 6: FSH Assay Method General Overview All compounds were stored in 96-well deepwell plates in DMSO at a nominal concentration of 10 mM (assuming perfect synthesis and yields). Compounds were screened for agonist activity at the FSH receptor using the recombinant FSH receptor stably transfected and expressed in Chinese Hamster Ovary cells (CHO cells) essentially as described in the work by Kelton, et al. (Molecular and Cellular Endocrinology, 1992, 89, 141-151). Since the FSH receptor is known to act via a G- H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 31 protein (Gs) to activate adenylyl cyclase and hence raise intracellular levels of cAMP, the high throughput screening (HTS) assay used a gene reporter system consisting of the cAMP response element coupled upstream to the reporter gene, which in this case encoded the enzyme luciferase. An agonist at the FSH receptor increases cAMP in the cell, which results in activation of CREB (cAMP response element binding protein).
This molecule interacts with the CRE element upstream of the gene and results in increased transcription of the genes downstream of the element. The substrate for luciferase (Packard Instrument Company, Meriden, CT, USA) was added to the cells after appropriate incubation with the compounds of the invention or FSH (used as a positive control). The amount of luciferase expressed was measured by quantitating the luminescence produced by the enzyme using a TopCount scintillation/luminescence counter running in single photon counting mode. A compound that acts as an agonist at the receptor should produce light from the treated cells in proportion to its concentration within the incubation. Luminescence should be saturable at high concentrations of the compound.
HTS Primary Assay in detail.
The compounds of the invention, in deepwell plates (Master plates) were loaded on the robotic deck along with the appropriate number of assay plates and daughter plates. A 10 p.1 aliquot from each master plate was transferred to the corresponding daughter plate and 90 p.I of DME/F12 was added and mixed within each well. 20 g1 was then removed from the daughter plate and dispensed into the assay plate. After addition of an aliquot of FSH (equivalent to an EC 100 response for this hormone [Final concentration of 5e-11 to each of three wells on the plate, 80 1ll of media (DME/F12 2% serum) and 100 jil aliquot of cells (4 x 10 5 /mL in the same media) were added and the plate incubated at 37 °C for 3 h 30 min. At this time the plate was removed from the incubator and media in each well was aspirated and the cells adhering to the bottom of the plate washed with 300 1 PBS containing 1 mM Ca 2 and 1 mM Mg 2 The PBS was aspirated and 100 g1 PBS added to each well. 100 p1 of Luclite (prepared as described by the manufacturer) was added to each well and the plate was shaken gently for 40 s prior to placement in the Topcount plate reader. After allowing 3.5 min for the plate to dark-adapt within the machine, the amount of luminescence generated was quantitated using Single Photon Counting mode. The data was transmitted electronically from the Topcount to the robot processing computer terminal and was renamed with an ID corresponding to the original master plate ID. Data were evaluated using an Excel macro and compounds showing activity comparable to that produced by an EC 100 of FSH itself were further analyzed in the H,\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 32 same assay at differing concentrations. LDR (log-dose-response) curves were generated for these compounds in CHO cells containing the FSH receptor and these curves were also compared with those in either cells expressing a different Gs-linked receptor or in cells lacking any transfected receptor (to confirm receptor specificity).
Compounds that showed receptor specificity and activity at low concentrations were progressed to secondary assays that included dose-response curves in Y1 cells co-expressing the human FSH receptor or in isolated rat granulosa cells.
Figure 6 displays results of the FSH assay for compounds XVI, XVII and XIX.
For comparison, results for FSH are also shown. Dose-response curves for each compound were generated and are displayed. From the graph, FSH has a ECso of 1.47 pM, compound XVI has a EC 50 of 38.8 nM, compound XVII has a ECso of 3.9 nM, and compound XIX has a EC 50 of 1.12 jpM. A best-fit line is drawn for FSH. Results of the assay using media only and forskolin are also shown. The assay was performed using duplicate samples of each compound.
Example 7: Rat Granulosa Cell assay The primary rat granulosa cell bioassay for FSH was performed essentially as described (Dahl et al. (1989) Methods Enzymol., 168: 414-423). Conversion of testosterone to estradiol in the presence of low nanomolar concentrations of FSH was detected using this assay. In this in vitro assay, conversion of androstendione to estrogen by granulosa cells in the presence of FSH was measured for compounds XVI and XVII. For comparison, FSH was also tested in the assay.
Cells were plated at 5000, 8000, 10,000 and 20,000 cells/ well/ 200 pJ of GAB medium on poly-D-lysine-coated 96-well tissue culture plates. Plates were incubated at 37 OC in a 5% C0 2 /95% air incubator for 3 days. Cultures were washed prior to stimulation with FSH or LH. 50 pl of 4X concentrations of rhFSH, rhLH or forskolin was added to the cultures. To define the range of the dose response curve the rhFSH was diluted so that the final concentration on the cells was between 10" 7 to 1015 M with three doses per log at 1, 2 and 5. Forskolin was diluted so that the final concentration on the cells was 1 pM. Cells were incubated 37 OC in 5% CO 2 Three days later, cell supernatants were collected and diluted 1:100 in GAB medium for measurement of estradiol by RIA. The RIA was performed according to manufacturer's directions except that an estradiol standard was prepared in absolute ethanol at 100 ng/mL and then further diluted in GAB medium, instead of kit buffer. The concentration of hormone was plotted on the X-axis against the amount of estradiol produced by the cells on the Y-axis using Origin graphics software.
As displayed in Figure 7, compounds XVI and XVII show increasing estradiol H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 33 production with increasing dose at concentrations between 200 nM and 5 gM. Above this concentration the compound showed a decrease in production-presumably since it caused a desensitization of the FSH receptors to further stimulation. The results show that compounds XVI and XVII stimulated estradiol production with EC 50 of 1.4 gM and 1.2 tM, respectively. Results of the assay using media only are also shown.
Example 8: Table of compounds of formula IV-A or IV-B The following compounds can be synthesized using the corresponding BOCprotected amino acid in the method set out in Figure 1 and Example 1.
o ECso (pM) ECso (gM) Structures Nomenclature CHOFSHR Rat Luciferase Granulosa (Example 6) (Example 7) o o 2-Oxo-6- N Lpentyl-2Ho--o N\ N pyran-3 0.077 0.96 carboxylic acid S/ [1-(9-ethyl-9Hcarbazol-3-yl carbamoyl)ethyl]-methylamide o o 2-Oxo-6- C.o pentyl-2Hpyran-3 3.1 carboxylic acid [1-(9-ethyl-9Hcarbazol-3-yl carbamoyl)ethyl]-methylamide H.\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 34 H \ShonaI\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 35 1 T -r 2-Oxo-6pentyl-2Hpyran-3carboxylic acid [1 -(9-ethyl-9Hcarbazol-3-yl carbamoyl)-2phenyl-ethyl]methyl-amide 2-Oxo-6pentyl-2Hpyran-3- 1.61 carboxylic acid [1 -(9-ethyl-9Hcarbazol-3-y carbamoyl)-3methyl-butyl]methyl-amide 2-Oxo-6pentyl-2Hpyran-3- 0.55 carboxylic acid [1 -(9-ethyl-9Hca rbazol-3-yI carbamoyl)-2methyl-p ropyl]methyl-amide I H:\Shonal\Keep\Speci\PS3478 DIVISIONAL SPECI 25/06/04 36 Structures INomenclature
EC
5 0
(I&M)
I CHOFSHR Luciferase (Example 6) 0 0 N N 0 H3C 2-Oxo-6-pentyl-2Hpyran-3-carboxylic acid 9 benzyisufanyl-1 ethyl-9H-carbazol-3ylcarbamoyi )-ethyl]amide 2-Oxo-6-pentyl-2Hpyran-3-carboxylic acid ethyl-[(9-ethyl- 9H-carbazol-3ylcarbamoyl)methyl]-amide -1 2-Oxo-6-pentyl-2Hpyran-3-carboxylic acid [1 -(9-ethyl-9Hcarbazo-3-yl carbamoyl)-1 methyl-ethyl]-amide 0 -q 2-Oxo-6-pentyl-2H-
H
3 C N N pyran-3-carboxylic HC acid [1-(9-ethyl-9H- 3.6 carbazol-3-y carbamoyl)cyclohexyl]-amide H:\ShonaI\Keep\S,eci\P53478 DIVISIONAL SPEC! 25/06/04 37 In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.
H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04
Claims (14)
1. A compound of Formula IVA, R 3 R 9 R4 Y xW I I R 5 Z R N' R2 IV-A and pharmaceutically acceptable addition salts thereof, wherein: R 3 and R 9 are each independently hydrogen, halogen, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, C1-C5 alkyl or alkenyl or arylalkyl imino, azido, mercapto, carboxamido, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, C,-C 8 alkyl, C1-C8 alkenyl, Cj-C8 alkoxy, C1-C8 alkoxycarbonyl, C2-C8 acyl, 1-C8 alkylthio, arylalkylthio, arylthio, C1-C alkylsulfinyl, arylalkylsulfinyl, arylsulfinyl, C 1 -C 8 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, C1-C6 N-alkyl carbamoyl, C2-C15 N,N-dialkylcarbamoyl, alkyl or alkenyl or arylalkyl ester, C1-C7 cycloalkyl, aroyl, aryloxy, benzyloxy, benzyloxy substituted with one or more substituents, aryl, aryl substituted with one or more substituents, C3-C7 heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic or aromatic ring; or R 3 and R 9 are each independently -NR 6 R 7 Or -(CH2),NR 6 R 7 where s is 1-6 and R 6 and R are as defined in section of the definition of substituent, below; or R 3 and R 9 together form a substituted or unsubstituted C3-C7 cycloalkyl or C3-C7 heterocycle spiro ring, or such a ring fused to a cycloalkyl, heterocyclic or aromatic ring, to make a compound of Formula IV-B, Y W I N R51Z R1 N R2 IV-B R' is a carbazolyl substituted with one or more substitutents; R 5 is a heterocyclic ring substituted with one or more substitutents; R 4 is hydrogen, C 1 -Co 1 0 alkyl, C 1 -Clo 0 alkyl substituted with one or more substituents, C2- alkenyl, C2-C10 alkenyl substituted with one or more substituents, C2-C10 akynyl, C2- H,\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 39 akynyl substituted with one or more substituents, Cj-C8 alkoxy, C1-Ca alkoxy substituted with one or more substituents, C2-C8 alkoxycarbonyl, C2-C8 alkoxycarbonyl substituted with one or more substituents, C-C8 thioalkyl, C1-C thioalkyl substituted with one or more substituents, C2-Ca acyl, 2-C8 acyl substituted with one or more substituents, C2-C8 acyloxy, C2-C8 acyloxy substituted with one or more substituents, aryloxy, aryl, aryl substituted with one or more substituents, C3-C7 cycloalkyl, C3-C7 cycloalkyl substituted with one or more substituents, C3-C7 heterocycle, or C3-C7 heterocycle substituted with one or more substituents, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic or aromatic ring; R 2 is hydrogen, straight or branched C1-C6 alkyl or C3-C7 cycloalkyl or C3-07 cycloalkyl substituted with one or more substituents, C3-C7 heterocycle, C3-C7 heterocycle substituted with one or more substituents, aryl, aryl substituted with one or more substituents, heteroaryl, heteroaryl substituted with one or more substituents, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic or aromatic ring; W is carbonyl amido amidoalkyl (NH(C=0)CH2-), imino (C=NH), thiocarbonyl sulfonyl (SO 2 methylene (CH 2 or methylene substituted with one or more substituents; Y is CH or N; Z is carbonyl amino imino sulfonyl (S02), or (C=O)NH; and the substituents for R 1 R 3 and R 4 are independently halogen, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, Cj- alkyl or alkenyl or arylalkyl imino, carbamoyl, azido, carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, C 1 -Cs alkyl, C,-C8 alkenyl, C-C8 alkoxy, C- C8 alkoxycarbonyl, aryloxycarbonyl, C2-C8 acyl, 1-C8 alkylthio, arylalkylthio, arylthio, CI-C8 alkylsulfinyl, arylalkylsulfinyl, arylsulfinyl, C,-C8 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, C-C6 N-alkyl carbamoyl, C2-C15 N,N-dialkylcarbamoyl, C3-C7 cycloalkyl, aroyl, aryloxy, arylalkyl ether, aryl, aryl fused to a cycloalkyl or heterocycle or another aryl ring, C3-C7 heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic, or aromatic ring; or NR 6 R 7 where R 6 and R 7 are each independently hydrogen, cyano, oxo, carboxamido, amidino, C-C8 hydroxyalkyl, C 1 -C 3 alkylaryl, aryl-C1-C 3 alkyl, C 1 -Cs alkyl, C-C8 alkenyl, C-C alkoxy, C1-C alkoxycarbonyl, aryloxycarbonyl, aryl- C1-C3 akoxycarbonyl, C2-C8 acyl, 01-C8 alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, aroyl, aryl, aryl fused to a cycloalkyl or heterocyclic or another aryl ring, C3-C7 cycloalkyl, C3- C7 heterocycle, or any of these rings fused or spiro-fused to a cycloakyl or heterocyclic or aromatic ring; or R6 and R' are taken together to form -(CH 2 )mB(CH 2 )n where B is -C(H)(R 8 H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 40 or where m and n are independently 1 to 3, r is 0 to 2, and R 8 is defined the same way as R 6 or -(CH 2 XsNR 6 R 7 where s is 1-6 and R6 and R 7 are as defined in section of the definition of substituent, above; and the substituents for R 5 are independently halogen, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, C- alkyl or alkenyl or arylalkyl imino, carbamoyl, azido, carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, C 1 -C8alkyl, C1-C8 alkenyl, C1-C8 alkoxy, Cj- C alkoxycarbonyl, aryloxycarbonyl, C2-C8 acyl, 01-08 alkylthio, arylalkylthio, arylthio, C1-C8 alkylsulfinyl, arylalkylsulfinyl, arylsulfinyl, C1-C alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, C1-C, N-alkyl carbamoyl, C2-C15 N,N-dialkylcarbamoyl, C3-C7 cycloalkyl, aroyl, aryloxy, arylalkyl ether, aryl, aryl fused to a cycloalkyl or heterocycle or another aryl ring, C3-C7 heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic, or aromatic ring; or -NR 6 R, where R 6 and R 7 are each independently hydrogen, cyano, oxo, carboxamido, amidino, C1-Cs hydroxyalkyl, C 1 -C 3 alkylaryl, aryl-C 1 -C 3 alkyl, C1-C8 alkyl, C 1 -C8 alkenyl, C 1 -C alkoxy, C-C alkoxycarbonyl, aryloxycarbonyl, aryl- C1-C3 akoxycarbonyl, C1-Cs alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, aroyl, aryl, aryl fused to a cycloalkyl or heterocyclic or another aryl ring, C3-07 cycloalkyl, C3-C7 heterocycle, or any of these rings fused or spiro-fused to a cycloakyl or heterocyclic or aromatic ring; or R 6 and R 7 are taken together to form -(CH 2 )mB(CH 2 )n where B is -C(H)(R 8 N(R 8 or where m and n are independently 1 to 3, r is 0 to 2, and R" is defined the same way as R 6 or -(CH 2 )sNR 6 R 7 where s is 1-6 and R6 and R 7 are as defined in section of the definition of substituent, above.
2. A compound according to Claim 1 of Formula XIV-A or Formula XIV-B, R12 R3 CH R 2 R 1 M R 13 4 R 3 R" M N N R' or R2 Z ON NR XIV-A XIV-A XIV-B H:\Shona\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 41 wherein R 2 R 3 R 4 R 5 and Z are as defined in claim 1; M is OH, N, 0, or S, provided when M is 0 or S there is no R1 R 11 R 12 ,and R 1 3 are each independently hydrogen, halogen, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, Cj-C 5 alkyl or alkenyl or arylalkyl imino, azido, mercapto, carboxamido, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, 01-08 alkyl, jC alkenyl, 01-08 alkoxy, 01-08 alkoxycarbonyl, 02-Ca acyl, 0j-C8 alkylthio, arylalkylthio, arylthio, Cl-Ca alkylsulfinyl, arylalkylsulfinyl, arylsulfinyl, Cl-C~ alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, Cj-C6 N-alkyl carbamoyl, 02-C 15 N, N-dialkylcarbamoyl, 01-05 alkyl or alkenyl or arylalkyl ester, 01-07 cycloalkyl, aroyl, aryloxy, benzyloxy, benzyloxy substituted with one or more substituents, aryl, aryl substituted with one or more substituents, 03-07 heterocycle, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclic or aromatic ring, or -NR 6 R 7 or -(CH 2 )NR 6 R 7 where s is 1-6 and R 6 and R 7 are as defined in section of the definition of substituent; or R 11 R 12 and R'1 3 each either independently or in combination are a spiro, fused, or bridged ring.
3. A compound according to Claim 2 selected from the group consisting of: 1 3 9 -Ethylcarbazolyl)carbamoylethylaminoNmethyl(2oxo6pentyl-2H- pyran-3-carboxamide); 1 -Methyl-i -[3-(9-ethylcarbazolyl )carbamoyl]-ethylamino-N-methyl-(2-oxo-6 pentyl- 2H-pyran-3-carboxamide); 1 -[3-(9-Ethylcarbazolyl)carbamoyl]isayaioN-ehl(-xo6pny-H pyran-3-ca rboxamide); 1 -j 3 9 -Ethylcarbazolyl)carbamoyl]isobutylaminoNmethyl(2oxo6pentyl-2H. pyran-3-carboxamide); 1 -[3-(9-Ethylcarbazolyl )carbamoyl]phenylethylamino-Nmethyl(2oxo-6pentyl. 2H- pyran-3-carboxamide); 1 3 9 -Ethylcarbazolyl)carbamoyl]2hydroxyethylaminoNmethyl.(2-oxo-6 pentyl- 2H-pyran-3-carboxamide); 1 -[3-(9-Ethylca rbazolyl )carbamoyl] methylamino-N-methyl-(2-oxo-6-pentyl-2H- pyran-3-carboxamide); 1 3 9 -Ethylcarbazolyl)carbamoyl~methylamino-Nethyl(2oxo-6-pentyl.2H- pyran-3-carboxamide); and 1 -Methyl-i 3 9 -ethylcarbazolyl)carbamoyl-ethylamino(2oxo6pentyl-2H- pyran-3-carboxamide); or a pharmaceutically acceptable addition salt thereof. H:\Shona1\Keep\SPeci\P53478 DIVISIONAL SPECI 25/06/04 42
4. A compound according to any one of Claims 1 to 3 for use as a medicament.
Use of a compound according to any one of Claims 1 to 3 in the manufacture of a medicament.
6. Use according to Claim 5, wherein the medicament exerts an FSH agonistic activity.
7. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 3 and a pharmaceutically acceptable carrier, diluent or excipient thereof.
8. A pharmaceutical composition comprising a compound as claimed in any one of Claims 1 to 3 and a pharmaceutically acceptable carrier, diluent or excipient thereof, in combination with FSH.
9. A pharmaceutical composition comprising a compound as claimed in any one of Claims 1 to 3 and a pharmaceutically acceptable carrier, diluent or excipient thereof, in combination with Clomiphene citrate.
A pharmaceutical composition comprising a compound as claimed in any one of Claims 1 to 3 and a pharmaceutically acceptable carrier, diluent or excipient thereof, in combination with human chononic gonadotropin (hCG) or human pituitary leutenizing hormone (LH).
11. A method for treating infertility comprising administering an effective FSH agonistic amount of a compound according to any one of Claims 1 to 3 or a composition according to any one of Claims 7 to 10 to a subject in need thereof.
12. Use of a compound according to any one of Claims 1 to 3 or a compound according to any one of Claims 7 to 10 in the manufacture of a medicament to treat infertility.
13. Use of a compound according to any one of Claims 1 to 3 or a compound according to any one of Claims 7 to 10 to treat infertility. H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04 43
14. Compounds of formula I, pharmaceutical compositions comprising them, or methods or uses involving them, substantially as herein described with reference to any one of the accompanying examples and/or figures. Dated this 2 5 th day of June 2004 APPLIED RESEARCH SYSTEMS ARS HOLDING NV By their Patent Attorneys GRIFFITH HACK Fellows Institute of Patent and Trade Mark Attorneys of Australia H:\Shonal\Keep\Speci\P53478 DIVISIONAL SPECI 25/06/04
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/095712 | 1998-08-07 | ||
PCT/US1999/017755 WO2000008015A2 (en) | 1998-08-07 | 1999-08-05 | Fsh mimetics for the treatment of infertility |
AU53931/99A AU772373B2 (en) | 1998-08-07 | 1999-08-05 | FSH mimetics for the treatment of infertility |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU53931/99A Division AU772373B2 (en) | 1998-08-07 | 1999-08-05 | FSH mimetics for the treatment of infertility |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2004202858A1 AU2004202858A1 (en) | 2004-07-22 |
AU2004202858B2 true AU2004202858B2 (en) | 2006-07-06 |
Family
ID=39363830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2004202858A Ceased AU2004202858B2 (en) | 1998-08-07 | 2004-06-25 | FSH mimetics for the treatment of infertility |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2004202858B2 (en) |
-
2004
- 2004-06-25 AU AU2004202858A patent/AU2004202858B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2004202858A1 (en) | 2004-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6235755B1 (en) | FSH mimetics for the treatment of infertility | |
DE69533991T2 (en) | DIPEPTIDES THAT STIMULATE THE DISTRIBUTION OF GROWTH HORMONES | |
US7989634B2 (en) | Melanocortin receptor agonists | |
US7049296B2 (en) | Gamma-secretase inhibitors | |
SK152797A3 (en) | Heterocyclic compounds as leucocytes adhesion inhibitors, antagonists vla-4 and pharmaceutical composition containing the same | |
SK152697A3 (en) | Five-membered heterocyclic compounds as leucocytes adhesion inhibitors, antagonists vla-4 and pharmaceutical composition containing the same | |
RU2272034C2 (en) | 2-amino-n-{(1r)-2-[(3r)-3-benzyl-3-(n,n',n'-trimethylhydrazinocarbonyl)piperidine-1-yl]-1-(1h-indol-3-ylmethyl)-2-oxoethyl}-2-methylpropionamide or its pharmaceutically acceptable salt, pharmaceutical composition based on thereof and method for stimulation of growth hormone release from mammal hypophysis | |
TW553937B (en) | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | |
JPH04211095A (en) | Novel dipeptide, preparation thereof and use thereof as renin inhibitor in medication | |
AU3701099A (en) | Compounds with growth hormone releasing properties | |
KR20000068229A (en) | Stable non-hygroscopic crystalline form of N-[N-N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl] compounds | |
KR930007431B1 (en) | Orally active renin inhibitor | |
US7910556B2 (en) | PAR-2 agonist | |
US5140011A (en) | Amino acid derivatives which have renin inhibiting activity | |
CA2879870A1 (en) | Azaindolines | |
KR20150042792A (en) | Azaheterocycles as bir2 and/or bir3 inhibitors | |
AU2004202858B2 (en) | FSH mimetics for the treatment of infertility | |
CA2379282C (en) | Amido spiropiperidines promote the release of growth hormone | |
EP1380582A1 (en) | FSH mimetics for the treatment of infertility | |
EP1864994B1 (en) | Par-2 agonist | |
CA2013475A1 (en) | Amino acid derivatives | |
DD298109A5 (en) | INHIBITORS OF RETROVIRAL PROTEASES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |